The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Amarin CEO John Thero shrugged off the stock's decline on Monday, telling CNBC that any investor concerned about its latest clinical trial should take a better look at the data.
Shares of the biopharmaceutical company closed down 5.84 percent on Monday after hovering down roughly 7 percent much of the day.
"I think as people begin to understand our data better, they will appreciate that this drug does much more than lipid modification," Thero said on "Power Lunch."
Amarin shares finished the day at $19.82 after researchers began comparing the full study of the clinical trial for its fish oil capsule, Vascepa, released over the weekend, to September's preliminary results.
The stock surged 300 percent after those early results, which showed the drug could reduce cardiovascular events by 25 percent. Shares of Amarin hit a high of $23.34 last Tuesday and are up more than 380 percent year to date.
But researchers are concerned about whether mineral oil, which was given to the placebo group, negatively affected the placebo group's results, making the treatment group's data appear better.
Thero defended the results, saying the mineral oil was reviewed and approved by the Food and Drug Administration prior to the study.
"We believe in our data," he said. "We've presented our data at American Heart Association. It's important to have data subject to scientific debate."
Thero also leaned on a peer review by the New England Journal of Medicine. The journal concluded that the mineral oil "couldn't have explained this significant result," Thero said.
"We stand behind the results and the published results in the New England Journal of Medicine and believe that this is a therapy which is well positioned to help millions of people," he said.
Amarin is now working on its plan to grow its sales force by 250 and focus on operational execution, Thero said.
"I think that our execution will be recognized by the marketplace," he said.
— CNBC's Meg Tirrell contributed to this report.